250 billion yuan saved in 3 years!

Since its official establishment on May 31, 2018, the National Medical Insurance Administration has adjusted the national medical insurance drug catalog for 3 consecutive years, shortening the adjustment period from the longest 7 years to 1 year, and established a dynamic adjustment mechanism for the medical insurance catalog, adding a total of 433 new ones New drugs and good drugs entered the list, and 183 drugs with inaccurate efficacy and clinically easy to abuse were removed from the list

At the same time, it has organized 5 batches of national drug centralized procurement, covering 218 varieties, with an average drop of more than 50%.

In addition to these overall data, the Chinese Pharmaceutical Association and the Chinese Medical Insurance Research Association announced more at the "'Six Increases, Four Decreases One Guarantee'-Blue Book Press Conference on the Progress and Effectiveness of Medical Insurance Drug Administration Reform" held today.

01After the dynamic adjustment of the medical insurance catalogue, oncology drugs increased and innovative drugs entered faster

By tracking and analyzing the use of drugs in 804 hospitals (including 596 tertiary hospitals and 218 second-level hospitals) in 31 provinces in China, combined with national data, the Science and Technology Development Center of the Chinese Pharmaceutical Association found that not only the use of drugs in the medical insurance catalog The proportion continues to increase, and the medication structure of medical institutions is also more reasonable

Comparing the Top 20 in terms of the amount of drugs used by medical institutions in the first quarter of 2015 and 2021, it can be found that the national key monitoring drugs have all disappeared, and the number of anti-tumor drugs, neurologic drugs, and blood system drugs has increased, indicating the amount of drugs used in China and the burden of disease.

Take diabetes medicines as an example.

As tumor diseases are an important cause of patients' poverty and return to poverty due to illness, medical insurance funds have been tilted towards anti-tumor drugs for years

In 2019, PD-1 tumor immunotherapy drugs entered medical insurance for the first time

Another type of "concerned" by the medical insurance catalogue is drugs for rare diseases

Drugs such as bosentan and magnastat were successfully negotiated in 2019, and patients with rare diseases such as pulmonary hypertension and type C Niemann-Pick disease have since been free from the predicament of no drugs available in the catalog

In addition, with the establishment of the dynamic adjustment mechanism of the medical insurance catalog, the time from the launch of innovative drugs to the entry of medical insurance has been significantly shortened

02After the centralized procurement of medicines by the country, the share of generic drugs has risen rapidly, and the per capita cost of drugs has dropped sharply

Since 2018, the state has organized 5 batches of centralized procurement of drugs, covering 218 varieties.

The number of users of selected drugs in centralized procurement has increased significantly

It is worth noting that the market share of generic drugs selected in centralized procurement has increased rapidly, which has strongly promoted the replacement of original research drugs by generic drugs

Although the amount of drugs used in centralized procurement has increased significantly, the amount used has gradually decreased, realizing a high-efficiency replacement of medical insurance funds

Although the prices of medicines are reduced, the quality is still worthy of guarantee